Knight Therapeutics (TSE:GUD) Price Target Raised to C$7.45 at Stifel Nicolaus

Knight Therapeutics (TSE:GUD) had its target price increased by investment analysts at Stifel Nicolaus from C$6.25 to C$7.45 in a research report issued to clients and investors on Tuesday,BayStreet.CA reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ target price would indicate a potential upside of 24.17% from the company’s current price.

Several other brokerages have also weighed in on GUD. Research Capitl raised Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 11th. Canaccord Genuity Group lowered shares of Knight Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday. One analyst has rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of C$7.48.

Knight Therapeutics Stock Performance

GUD traded up C$0.03 during midday trading on Tuesday, reaching C$6.00. The company had a trading volume of 41,913 shares, compared to its average volume of 71,326. The business has a 50-day moving average price of C$5.69 and a two-hundred day moving average price of C$5.58. The company has a debt-to-equity ratio of 7.52, a quick ratio of 1.79 and a current ratio of 3.36. Knight Therapeutics has a 12-month low of C$5.09 and a 12-month high of C$6.45. The stock has a market cap of C$606.90 million, a PE ratio of -20.03, a P/E/G ratio of -1,013.50 and a beta of 0.50.

Insider Buying and Selling

In other news, insider Sime Armoyan sold 2,500,000 shares of Knight Therapeutics stock in a transaction dated Friday, March 21st. The stock was sold at an average price of C$6.30, for a total transaction of C$15,750,000.00. In the last 90 days, insiders have sold 3,143,300 shares of company stock valued at $19,733,740. Company insiders own 45.62% of the company’s stock.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.